Phase 2Terminated
PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer (RELEASE)
A Multi-Center Randomised Open-Label Phase 2 Study to Assess the Safety, Tolerability and Efficacy of Fimaporfin-Induced Photochemical Internalisation of Gemcitabine Complemented by Gemcitabine/Cisplatin Chemotherapy Versus Gemcitabine/Cisplatin Alone in Patients With Inoperable Cholangiocarcinoma
- Sponsor
- PCI Biotech AS (Industry)
- Enrollment
- 41 enrolled
- Conditions
- Cholangiocarcinoma
- Interventions
- Fimaporfin and Gemcitabine; Gemcitabine/Cisplatin chemotherapy
- Ages
- adults, older adults
- Registry
- NCT04099888
Full record on ClinicalTrials.gov
From the registry
This study will assess the safety and effectiveness of fimaporfin-induced photochemical internalisation (PCI) of gemcitabine complemented by systemic gemcitabine/cisplatin chemotherapy compared to gemcitabine/cisplatin alone, in patients with inoperable cholangiocarcinoma (CCA). Participants will be randomly assigned to one of the treatment groups and will receive study treatment for 6 months, followed by assessments every 3 months, as applicable.
Primary outcomes
- Progression-free Survival (PFS)
History
Results first posted
Last registry update
Study completion
Primary completion
Registered
Started